Patents Examined by Yong Chu
  • Substituted 3-alkyl and 3-alkenyl azetidine derivatives
    Patent number: 7906503
    Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
    Type: Grant
    Filed: October 21, 2008
    Date of Patent: March 15, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Robert K. Baker, Jianming Bao, Shouwu Miao, Kathleen M. Rupprecht
  • Non-nucleoside reverse transcriptase inhibitors
    Patent number: 7906540
    Abstract: Compounds of formula I, wherein R1, R2, R3, R4, R5, X, Y, and Ar are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: March 15, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Zachary Kevin Sweeney, Michael Welch
  • Diaminotriazoles useful as inhibitors of protein kinases
    Patent number: 7902239
    Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 9, 2007
    Date of Patent: March 8, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Albert C. Pierce, Michael Arnost, Robert J. Davies, Cornelia J. Forster, Vincent Galullo, Ronald Grey, Jr., Mark Ledeboer, Shi-Kai Tian, Jinwang Xu, Hayley Binch, Brian Ledford, David Messersmith, Suganthi Nanthakumar, Andrew Jayaraj, Greg Henkel, Francesco G. Salituro, Jian Wang
  • ?-butyrolactone compound and pharmaceutical composition thereof
    Patent number: 7902255
    Abstract: A ?-butyrolactone compound as shown in Formula (I) and pharmaceutical composition thereof: wherein X?N, O, S, Se; and A and B are selected from substituents having the following formula: wherein R1, R2, R3, R4, and R5 are selected from a hydrogen atom, a halogen atom, a hydroxyl group, a mercapto group, an amino group, an alkoxy group, and a nitro group. The ?-butyrolactone compound and pharmaceutical composition thereof butyrolactone have inhibitory effects on hepatoma, ovarian cancer, breast cancer, lung cancer, malignant glioblastoma or colorectal carcinoma, and are cytotoxic with high specificity to inhibit Paclitaxel-resistant tumor cells at later stage of chemotherapy without any damage on normal cells.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: March 8, 2011
    Assignee: Tzu Chi Buddhist General Hospital
    Inventors: Shinn-Zong Lin, Horng-Jyh Harn
  • Compounds 010
    Patent number: 7902181
    Abstract: The present invention provides compounds of formula (I) in which n, y, X1, X2, A, B, R1, R2, R3, R4 and R5 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: December 10, 2008
    Date of Patent: March 8, 2011
    Assignee: AstraZeneca AB
    Inventors: Mark Furber, Christopher Andrew Luckhurst, Hitesh Jayantilal Sanganee, Linda Anne Stein, Peter Alan Cage
  • Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
    Patent number: 7902378
    Abstract: The present invention relates to carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy) ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates thereof, compositions containing the aforementioned salts and/or solvates, and methods of using the aforementioned salts and/or solvates to treat hypertension, congestive heart failure and angina, etc.
    Type: Grant
    Filed: June 25, 2007
    Date of Patent: March 8, 2011
    Assignee: SmithKline Beecham (Cork) Limited
    Inventors: Christopher S. Brook, Wei Chen, Philip C. Dell'Orco, Lee M. Katrincic, Ann Marie Louvet, Choon K. Oh, Paul G. Spoors, Christopher Werner
  • Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
    Patent number: 7897625
    Abstract: The invention relates to carbamoylbenzotriazole derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: March 1, 2011
    Assignee: Sanofi-Aventis
    Inventors: Stefan Petry, Gerhard Zoller, Norbert Tennagels, Günter Müller
  • Stilbene derivatives, light-emitting element and light-emitting device
    Patent number: 7898171
    Abstract: The present invention provides a novel substance having an excellent color purity of blue, a light-emitting element and a light-emitting device using the novel substance. A stilbene derivative has a structure shown by the general formula (1). In the general formula (1), R1 is hydrogen, an alkyl group having 1 to 4 carbon atoms, or an aryl group having 6 to 25 carbon atoms. R2 is an alkyl group having 1 to 4 carbon atoms or an aryl group having 6 to 25 carbon atoms. Each of R3 to R5 is hydrogen or an alkyl group having 1 to 4 carbon atoms. Ar1 is an aryl group having 6 to 25 carbon atoms.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: March 1, 2011
    Assignee: Semiconductor Energy laboratory Co., Ltd.
    Inventors: Masakazu Egawa, Harue Nakashima, Sachiko Kawakami, Nobuharu Ohsawa, Satoshi Seo, Ryoji Nomura
  • 1,3-Diiodohydantoin compound and production method thereof
    Patent number: 7897785
    Abstract: The present invention provides a means which can inhibit release of I2 in production or storage of 1,3-diiodohydantoin compound, and thereby solve decrease in purity of the compound and various problems caused by I2. The present invention provides a production method for 1,3-diiodohydantoin compound comprising a step to prepare a wet body containing a 1,3-diiodohydantoin compound, and (1) a step to dry the wet body by contacting the wet body with heated gas or (2) a step to lyophilize the wet body, a storage method for 1,3-diiodohydantoin compound comprising a step to store a 1,3-diiodohydantoin compound under a temperature condition of 15° C. or lower, and a 1,3-diiodohydantoin compound wherein content of released I2 is 1% by mass or less.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: March 1, 2011
    Assignee: Nippoh Chemicals Co., Ltd.
    Inventors: Kazuhisa Inoue, Yukihiko Hanamura, Takaaki Miyazawa
  • Maleimide derivative
    Patent number: 7897787
    Abstract: A compound represented by the following general formula (I): [wherein R1 and R2 independently represent hydrogen atom, or a group represented by the following formula (A): (wherein X1 and X2 represent hydrogen atom, an alkyl group, an alkoxy group, or a halogen atom), provided that R1 and R2 do not simultaneously represent hydrogen atom; R3 and R6 represent an alkyl group; R4 and R7 represent hydrogen atom, an alkyl group, carboxy group, an alkoxycarbonyl group, or sulfo group; and R5 and R8 represents an alkyl group, an aryl group, an alkoxycarbonyl group, a vinyl group, a thienyl group, or a pyrrolyl group], or a salt thereof, which is usable for efficient screening for a chemical substance having applicability as a catalyst of the reaction of Michael addition.
    Type: Grant
    Filed: September 13, 2006
    Date of Patent: March 1, 2011
    Assignee: The University of Tokyo
    Inventors: Takuya Matsumoto, Takuji Shoda, Yasuteru Urano, Tetsuo Nagano
  • Chemical compositions and methods of making them
    Patent number: 7897800
    Abstract: Reaction products of polyfunctional compounds with two or more coordination elements are described.
    Type: Grant
    Filed: January 29, 2007
    Date of Patent: March 1, 2011
    Assignee: JR Chem, LLC
    Inventors: José E. Ramirez, Joseph Faryniarz
  • Processes for the preparation of DPP IV inhibitors
    Patent number: 7893103
    Abstract: The present invention relates to novel processes for preparing DPP-IV inhibitors having the structure of formula I, and pharmaceutically acceptable salt thereof, which are useful for treatment of Type 2 diabetes.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: February 22, 2011
    Assignee: Glenmark Pharmaceuticals, S.A.
    Inventors: Abraham Thomas, V. S. Prasada Rao Lingam, Ashok Bhausaheb Kadam, Suresh M. Kadam, Shantaram Kashinath Phatangare, Deepak Vitthal Ukride
  • Di-fluoro containing compounds as cysteine protease inhibitors
    Patent number: 7893112
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: April 1, 2008
    Date of Patent: February 22, 2011
    Assignee: Virobay, Inc.
    Inventors: John O. Link, Craig J. Mossman, Jie Liu, Soon Hyung Woo
  • Cyanin-type compounds having an alkynyl linker arm
    Patent number: 7892297
    Abstract: Cyanine-type fluorescent dyes modified with an alkynyl linker arm of formula (I), suitable for the conjugation of biomolecules, such as for example nucleosides, nucleotides, oligonucleotides, nucleic acids, proteins, peptides, vitamins and hormones. A method and intermediates for the synthesis of the alkynyl cyanines of the invention are also described, as well as alkynyl cyanine-biomolecule conjugates and methods for preparing thereof. The alkynyl cyanines can be advantageously used as markers for biomolecules or as quenchers.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: February 22, 2011
    Assignee: Cyanine Technologies S.p.A.
    Inventor: Giuseppe Caputo
  • 2-{2-[5-(3-chlorophenyl)]furanyl}-4,5-bis(4-methoxyphenyl)imidazole and methods for inducing differentiation of myoblasts or muscle fibers into neuron cells
    Patent number: 7888118
    Abstract: The present invention relates to 4,5-bis(4-methoxyphenyl)imidazole compound inducing differentiation of myoblasts or muscle fibers into neuron cells, a pharmaceutical composition including said compound, a method of inducing neuron cells differentiation and a screening method for identifying additional compound useful for inducing neuron cells differentiation. More specifically, it relates to 2-{2-[5-(3-chlorophenyl)]furanyl}-4,5-bis(4-methoxyphenyl)imidazole that induces differentiation of myoblasts or muscle fibers into neuron cells, all pharmaceutically acceptable isomers, salts, and a pharmaceutical composition including said compound, a method of inducing neuron cells differentiation and a screening method for identifying additional compound useful for inducing neuron cells differentiation.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: February 15, 2011
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: In-Jae Shin, Myung-Ryul Lee, Darren Williams
  • 2,4,6-phenyl substituted cyclic ketoenols
    Patent number: 7888285
    Abstract: The present invention relates to novel 2,4,6-phenyl-substituted cyclic ketoenols of the formula (I) in which W, X, Y and CKE have the meanings given in the disclosure, to a plurality of processes for their preparation and to their use as pesticides and/or herbicides. The invention further relates to selectively herbicidal compositions containing 2,4,6-phenyl-substituted cyclic ketoenols and a compound which improves crop plant tolerance.
    Type: Grant
    Filed: March 2, 2004
    Date of Patent: February 15, 2011
    Assignee: Bayer CropScience AG
    Inventors: Reiner Fischer, Klaus Kunz, Stefan Lehr, Michael Ruther, Udo Schneider, Markus Dollinger, Mark Wilhelm Drewes, Dieter Feucht, Jörg Konze, Ulrike Wachendorff-Neumann, Guido Bojack, Thomas Auler, Martin Jeffrey Hills, Thomas Bretschneider, Olga Malsam, Christoph Erdelen, Angelika Lubos-Erdelen, legal representative, Alfred Angermann, Heinz Kehne, Christopher Hugh Rosinger
  • 3-(phenoxyphenylmethyl)pyrrolidine compounds
    Patent number: 7888386
    Abstract: In one aspect, the invention relates to compounds of formula I: where a and R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: February 15, 2011
    Assignee: Theravance, Inc.
    Inventors: Eric L. Stangeland, Priscilla Van Dyke, Timothy J. Church, Lori Jean Patterson, Daisuke Roland Saito
  • Ureido-thiazole glucokinase activators
    Patent number: 7884210
    Abstract: The invention provides a compound of general formula (I) wherein the compounds are of the class ureido-thiazole glucokinase activators, useful for the treatment of various diseases, for example, type 2 diabetes.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: February 8, 2011
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Anthony Murray, Per Vedso, Marit Kristiansen, Lone Jeppesen
  • Process for the preparation of Telmisartan
    Patent number: 7884214
    Abstract: The present invention encompasses a method for the preparation of Telmisartan comprises, through Telmisartan dihydrochloride comprises i) Condensing 4-Methyl-2-n-propyl-1H-benzimidazole-6-carboxylic acid with N-Methyl-O-phenylenediamine dihydrochloride to yields 4-methyl-6 (1-methyl benzimidazol-2-yl)-2-n-propyl 1H-benzimidazole ii) Treating 4-methyl-6-(1-methylbenzimidazol-2-yl)-2-n-propyl-1H-benzimidazole with 4?-(bromomethyl)-2-biphenyl-2-carboxylate in presence of a base in an organic solvent and isolating the ester as acid addition salt iii) Converting ester acid addition salt to Telmisartan dihydrochloride and iv) Converting Telmisartan dihydrochloride to Telmisartan.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: February 8, 2011
    Assignee: Matrix Laboratories Limited
    Inventors: Satyanarayana Chava, Seeta Ramanjaneyulu Gorantla, Sai Prasanna Bhagya Lakshmi Ginjupalli
  • Use of bora-tetraazapentalenes
    Patent number: 7884209
    Abstract: The present invention relates to the use of bora-tetraazapentalenes with the general formula A as redox-dopant and/or emitter in electronic, optoelectronic or electroluminescent structural elements.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: February 8, 2011
    Assignee: Novaled AG
    Inventors: Andre Gruessing, Horst Hartmann